Free Trial

Halozyme Therapeutics (HALO) Competitors

Halozyme Therapeutics logo
$59.77 -2.15 (-3.47%)
Closing price 04:00 PM Eastern
Extended Trading
$59.22 -0.56 (-0.93%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HALO vs. BIIB, UTHR, BMRN, INCY, NBIX, EXEL, EXAS, MDGL, RGEN, and ALKS

Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), and Alkermes (ALKS). These companies are all part of the "biotechnology" industry.

Halozyme Therapeutics vs.

Biogen (NASDAQ:BIIB) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Biogen has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

In the previous week, Biogen had 9 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 32 mentions for Biogen and 23 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.30 beat Biogen's score of 1.14 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
22 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Halozyme Therapeutics
19 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen currently has a consensus price target of $213.33, suggesting a potential upside of 69.59%. Halozyme Therapeutics has a consensus price target of $62.78, suggesting a potential upside of 4.24%. Given Biogen's higher possible upside, equities analysts clearly believe Biogen is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
0 Sell rating(s)
18 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.42
Halozyme Therapeutics
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60

Biogen received 1288 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 71.44% of users gave Biogen an outperform vote while only 69.57% of users gave Halozyme Therapeutics an outperform vote.

CompanyUnderperformOutperform
BiogenOutperform Votes
1816
71.44%
Underperform Votes
726
28.56%
Halozyme TherapeuticsOutperform Votes
528
69.57%
Underperform Votes
231
30.43%

Halozyme Therapeutics has a net margin of 43.74% compared to Biogen's net margin of 16.87%. Halozyme Therapeutics' return on equity of 157.78% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen16.87% 14.98% 8.76%
Halozyme Therapeutics 43.74%157.78%25.34%

Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.68B1.90$1.63B$11.1911.24
Halozyme Therapeutics$1.02B7.33$281.59M$3.4317.56

87.9% of Biogen shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 2.9% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Halozyme Therapeutics beats Biogen on 10 of the 18 factors compared between the two stocks.

Remove Ads
Get Halozyme Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HALO vs. The Competition

MetricHalozyme TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$7.41B$2.90B$5.38B$7.14B
Dividend YieldN/A1.53%4.87%4.05%
P/E Ratio17.4929.4222.8217.35
Price / Sales7.33420.15353.9684.30
Price / Cash12.35168.6838.1634.64
Price / Book20.413.466.263.78
Net Income$281.59M-$72.06M$3.21B$247.18M
7 Day Performance-5.66%-13.22%-7.92%-7.74%
1 Month Performance3.58%-20.48%-2.85%-10.35%
1 Year Performance51.58%-33.99%3.82%-7.76%

Halozyme Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HALO
Halozyme Therapeutics
4.1259 of 5 stars
$59.77
-3.5%
$62.78
+5.0%
+53.9%$7.38B$1.02B17.43390Positive News
BIIB
Biogen
4.839 of 5 stars
$136.84
-1.1%
$213.33
+55.9%
-36.7%$20.03B$9.68B12.238,720Analyst Downgrade
Positive News
UTHR
United Therapeutics
4.8566 of 5 stars
$308.27
+0.4%
$388.25
+25.9%
+32.9%$13.85B$2.88B13.54980Positive News
BMRN
BioMarin Pharmaceutical
4.8714 of 5 stars
$70.69
-1.0%
$94.00
+33.0%
-22.2%$13.49B$2.85B32.133,401Analyst Downgrade
News Coverage
Positive News
INCY
Incyte
4.6087 of 5 stars
$60.55
-0.1%
$74.88
+23.7%
+12.9%$11.72B$4.24B224.272,320Positive News
NBIX
Neurocrine Biosciences
4.8331 of 5 stars
$110.60
-2.3%
$165.38
+49.5%
-25.2%$11.03B$2.36B33.621,200Analyst Forecast
News Coverage
Positive News
Gap Down
EXEL
Exelixis
4.4246 of 5 stars
$36.92
+0.6%
$37.59
+1.8%
+54.8%$10.33B$2.17B20.861,220Positive News
Gap Down
EXAS
Exact Sciences
4.3574 of 5 stars
$43.29
-0.8%
$70.26
+62.3%
-39.2%$8.04B$2.76B-7.776,400Positive News
MDGL
Madrigal Pharmaceuticals
3.4411 of 5 stars
$331.23
+1.0%
$378.44
+14.3%
+33.4%$7.31B$180.13M-13.2190Positive News
Gap Down
RGEN
Repligen
4.6574 of 5 stars
$127.24
-4.6%
$178.64
+40.4%
-31.4%$7.14B$634.44M-249.492,020Positive News
Gap Down
ALKS
Alkermes
4.762 of 5 stars
$33.02
-0.6%
$39.38
+19.3%
+20.2%$5.37B$1.56B15.221,800Gap Down
Remove Ads

Related Companies and Tools


This page (NASDAQ:HALO) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners